During all the mechanisms that regulate the dyslipidemia, PCSK9 inhibition has been verified as a biological target in enhancing serum cholesterol clearance, companying with improving the hypercholesterolemia of obese patients [10, 49, 50]. Here, PCSK9 is linked to metabolic syndrome.